Meeting
2023 ASCO Annual Meeting
A phase I study of nelmastobart (hSTC810), an anti-BTN1A1 antibody, in patients with advanced solid tumors.
Authors
Soohyeon Lee
Korea University Anam Hospital, Seoul, South Korea
Soohyeon Lee , Sangjoon Shin , Patricia LoRusso , Christian Diego Rolfo , Hyunjin Jung , Stephen Sunghan Yoo , David S. Hong
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Other Checkpoint Inhibitors (Non-PD1/PDL1, Monotherapy, or Combination)
Clinical Trial Registration Number
NCT05231746
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2633)
DOI
10.1200/JCO.2023.41.16_suppl.2633
Abstract #
2633
Poster Bd #
475
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Phase I study of weekly oral docetaxel (ModraDoc001) plus ritonavir in patients with advanced solid tumors.
First Author: Serena Marchetti
Poster
2023 ASCO Annual Meeting
Sudocetaxel zendusortide (TH1902), a novel sortilin-receptor (SORT1)-targeting peptide-drug-conjugate (PDC) in patients (pts) with advanced solid tumors: Results from part 1 (dose-escalation) of a phase 1, open-label study.
First Author: Funda Meric-Bernstam
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Trials in progress: A phase 1, open-label, pharmacokinetic, safety and tolerability study of PF-07265807 (selective TAM kinase inhibitor) alone or with sasanlimab in patients with advanced or metastatic solid tumors.
First Author: Jessica Dreger McDermott
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Safety and preliminary efficacy of MIL93 in patients with advanced solid tumors: The monotherapy part of a phase 1 trial.
First Author: Jing Huang